164 related articles for article (PubMed ID: 12568645)
21. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Hillebrand MJ; Bosch TM; Lopez-Lazaro L; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2007 May; 59(6):825-37. PubMed ID: 16988825
[TBL] [Abstract][Full Text] [Related]
23. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Lopez-Lazaro L; Beijnen JH; Schellens JH
Invest New Drugs; 2005 Oct; 23(5):429-36. PubMed ID: 16133794
[TBL] [Abstract][Full Text] [Related]
24. ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF; Glover K
Curr Opin Investig Drugs; 2001 Nov; 2(11):1631-8. PubMed ID: 11763168
[TBL] [Abstract][Full Text] [Related]
25. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Lau L; Supko JG; Blaney S; Hershon L; Seibel N; Krailo M; Qu W; Malkin D; Jimeno J; Bernstein M; Baruchel S
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):672-7. PubMed ID: 15701855
[TBL] [Abstract][Full Text] [Related]
26. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of ET-743: the French experience.
Brain EG
Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
[TBL] [Abstract][Full Text] [Related]
28. Science and serendipity in cancer research.
Smyth JF
Eur J Cancer; 2001 Jan; 37(1):8. PubMed ID: 11165123
[No Abstract] [Full Text] [Related]
29. Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins.
Jin W; Metobo S; Williams RM
Org Lett; 2003 Jun; 5(12):2095-8. PubMed ID: 12790537
[TBL] [Abstract][Full Text] [Related]
30. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
32. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
33. Progress in the development and acquisition of anticancer agents from marine sources.
Amador ML; Jimeno J; Paz-Ares L; Cortes-Funes H; Hidalgo M
Ann Oncol; 2003 Nov; 14(11):1607-15. PubMed ID: 14581267
[No Abstract] [Full Text] [Related]
34. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
Wright BJ; Chan C; Danishefsky SJ
J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
[TBL] [Abstract][Full Text] [Related]
35. New drugs from the sea.
D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.
Blay JY; Le Cesne A; Verweij J; Scurr M; Seynaeve C; Bonvalot S; Hogendoorn P; Jimeno J; Evrard V; van Glabbeke M; Judson I
Eur J Cancer; 2004 Jun; 40(9):1327-31. PubMed ID: 15177491
[TBL] [Abstract][Full Text] [Related]
37. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.
Hurley LH; Zewail-Foote M
Adv Exp Med Biol; 2001; 500():289-99. PubMed ID: 11764956
[TBL] [Abstract][Full Text] [Related]
38. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Martinez EJ; Owa T; Schreiber SL; Corey EJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3496-501. PubMed ID: 10097064
[TBL] [Abstract][Full Text] [Related]
39. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
40. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.
Zewail-Foote M; Hurley LH
J Med Chem; 1999 Jul; 42(14):2493-7. PubMed ID: 10411470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]